Lucid Diagnostics Inc.

Lucid Diagnostics is a commercial-stage medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM) focused on early detection of esophageal precancer to prevent its progression to lethal cancer. Its EsoGuard Esophageal DNA Test and EsoCheck cell-collection device, exclusively licensed from Case Western Reserve University, received FDA clearance in 2019 and are supported by clinical guidance from the American College of Gastroenterology and American Gastroenterological Association. The company operates LucidDx Labs, a CLIA-certified, CAP-accredited clinical laboratory, and has traded on Nasdaq under the ticker LUCD since its October 2021 IPO.